PF-06939926 clinical trials

Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy

This study is testing a new gene therapy, PF-06939926, for boys aged 4-7 with Duchenne muscular dystrophy. It aims to see if the treatment is safe and effective in improving muscle function. Some boys will get the treatment right away, others will get a dummy treatment first, then the real treatment later.